High-Throughput assessment of ChIP-grade capability with Luminex xMAP technology

Speaker
  • Chief Scientific Officer, EpiCypher
    Biography
      Michael earned his PhD in Molecular Immunology from Imperial College London and completed postdoctoral studies in the Thrombosis Research Institute (London) and with Dr. Steve Buratowski at Harvard Medical School. Prior to joining EpiCypher he was a Principal Investigator in the Department of Cell Biology at Albert Einstein College of Medicine. His work has focused on many key oncology research areas including cell-cycle regulation, DNA repair, epigenetics, gene expression and genetic networks.

    Abstract

    Histone post-translational modifications (PTMs) play pivotal roles in chromatin dynamics and function, with alterations in the healthy profile associated with diverse human pathologies. The regulation and genomic distribution of PTMs is frequently studied by antibodies, despite the wide suspicion that a significant proportion of these reagents have specificity issues. To address this issue we have developed a high -sensitivity and -throughput approach that leverages the multiplexing ability of xMAP technology. We have created a library of >100 biotinylated PTM-containing designer nucleosomes (dNucs) that can be easily combined with Avidin-coated MagPlex beads and determined the binding profiles of >400 commercial ‘PTM-specific’ antibodies. Our results identify truly capable reagents to a large number of PTM targets, but also provide direct evidence that many antibodies in widespread use are highly cross-reactive. As such the current gold-standard screening approaches (immobilized histone PTM-peptide arrays) have proven poorly predictive of alternate assay platforms. In contrast Luminex assays with PTM-nucleosome substrates can be used to identify antibodies with true Chromatin Immuno- Precipitation (ChIP)-grade potential: this will be integral in creating new reagents to study these disease-relevant targets.


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    NOV 16, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    JUL 22, 2020 10:00 AM PDT
    C.E. CREDITS
    JUL 22, 2020 10:00 AM PDT
    DATE: July 23, 2020 TIME: 10:00 am PDT The SARS-CoV-2 pandemic has taken a toll on many sectors of the medical community. As the pandemic took a grip on the laboratory, the need for diagnost...
    OCT 29, 2020 6:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    Loading Comments...
    Show Resources